Publications by Janne Kærn
109 publications found
Original articles
Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study
Acta Obstet Gynecol Scand, 97 (8), 956-965
DOI 10.1111/aogs.13361, PubMed 29790149
Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial
Gynecol Oncol, 144 (1), 65-71
DOI 10.1016/j.ygyno.2016.11.006, PubMed 27871723
Impact of hospital type and treatment on long-term survival among patients with FIGO Stage IIIC epithelial ovarian cancer: follow-up through two recurrences and three treatment lines in search for predictors for survival
Eur J Gynaecol Oncol, 37 (3), 305-11
DOI 10.12892/ejgo3007.2016, PubMed 27352555
Fertility and gonadal function after adjuvant therapy in women diagnosed with a malignant ovarian germ cell tumor (MOGCT) during the "cisplatin era"
Gynecol Oncol, 136 (2), 224-9
DOI 10.1016/j.ygyno.2014.12.010, PubMed 25511159
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953
Malignant ovarian germ cell tumors: presentation, survival and second cancer in a population based Norwegian cohort (1953-2009)
Gynecol Oncol, 131 (2), 330-5
DOI 10.1016/j.ygyno.2013.08.028, PubMed 24001518
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974
Silencing of indoleamine 2,3-dioxygenase enhances dendritic cell immunogenicity and antitumour immunity in cancer patients
Int J Oncol, 43 (1), 280-8
DOI 10.3892/ijo.2013.1922, PubMed 23620105
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921
Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients
Br J Cancer, 107 (4), 588-91
DOI 10.1038/bjc.2012.307, PubMed 22836511
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409
First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)--a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG
Ann Oncol, 23 (10), 2613-2619
DOI 10.1093/annonc/mds060, PubMed 22539562
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
Hum Pathol, 43 (5), 669-74
DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113
miRNA profiling along tumour progression in ovarian carcinoma
J Cell Mol Med, 15 (7), 1593-602
DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115
Improved 5-year disease-free survival for FIGO stage I epithelial ovarian cancer patients without tumor rupture during surgery
Gynecol Oncol, 122 (1), 83-8
DOI 10.1016/j.ygyno.2011.02.038, PubMed 21435701
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
Tumour Biol, 32 (3), 589-96
DOI 10.1007/s13277-011-0157-6, PubMed 21350924
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408
Ovarian dysgerminomas are characterised by frequent KIT mutations and abundant expression of pluripotency markers
Mol Cancer, 6, 12
DOI 10.1186/1476-4598-6-12, PubMed 17274819
Expression of matrix metalloproteinase-2 in serous borderline ovarian tumors is associated with noninvasive implant formation
Eur J Gynaecol Oncol, 28 (5), 356-63
PubMed 17966213
Primary surgery for ovarian cancer
Eur J Surg Oncol, 32 (8), 844-52
DOI 10.1016/j.ejso.2006.03.036, PubMed 16677797
Chromosome 2q24.2 is lost in sporadic but not in BRCA1-associated ovarian carcinomas
Pathology, 38 (2), 145-51
DOI 10.1080/00313020600561526, PubMed 16680901
Influence of interval between primary surgery and chemotherapy on short-term survival of patients with advanced ovarian, tubal or peritoneal cancer
Gynecol Oncol, 102 (3), 447-52
DOI 10.1016/j.ygyno.2006.01.035, PubMed 16516277
Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals
Int J Gynecol Cancer, 16 Suppl 1, 11-7
DOI 10.1111/j.1525-1438.2006.00319.x, PubMed 16515561
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
Diagn Cytopathol, 33 (5), 332-7
DOI 10.1002/dc.20296, PubMed 16240397
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317
Prognostic factors in ovarian carcinoma stage III patients. Can biomarkers improve the prediction of short- and long-term survivors?
Int J Gynecol Cancer, 15 (6), 1014-22
DOI 10.1111/j.1525-1438.2005.00185.x, PubMed 16343177
Symptoms and referral of women with epithelial ovarian tumors
Int J Gynaecol Obstet, 88 (1), 31-7
DOI 10.1016/j.ijgo.2004.09.008, PubMed 15617702
No differences in p53 mutation frequencies between BRCA1-associated and sporadic ovarian cancers
Gynecol Oncol, 95 (3), 430-6
DOI 10.1016/j.ygyno.2004.08.035, PubMed 15581943
Evaluation of genomic changes in a large series of malignant ovarian germ cell tumors--relation to clinicopathologic variables
Cancer Genet Cytogenet, 155 (1), 25-32
DOI 10.1016/j.cancergencyto.2004.02.010, PubMed 15527899
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
Gynecol Oncol, 94 (1), 80-5
DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123
[Paclitaxel should be included in standard therapy of ovarian carcinoma]
Tidsskr Nor Laegeforen, 123 (21), 3083-4
PubMed 14618184
Large-scale genomic instability predicts long-term outcome for women with invasive stage I ovarian cancer
Ann Oncol, 14 (10), 1494-500
DOI 10.1093/annonc/mdg403, PubMed 14504048
Long-term follow-up confirms a survival advantage of the paclitaxel-cisplatin regimen over the cyclophosphamide-cisplatin combination in advanced ovarian cancer
Int J Gynecol Cancer, 13 Suppl 2, 144-8
DOI 10.1111/j.1525-1438.2003.13357.x, PubMed 14656271
First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin versus paclitaxel/carboplatin
Int J Gynecol Cancer, 13 Suppl 2, 172-7
DOI 10.1111/j.1525-1438.2003.13363.x, PubMed 14656276
Gestational trophoblastic tumors in Norway, 1968-1997: patient characteristics, treatment, and prognosis
Gynecol Oncol, 87 (1), 71-6
DOI 10.1006/gyno.2002.6801, PubMed 12468345
Placental site trophoblastic tumor (PSTT) in mother and child: first report of PSTT in infancy
Med Pediatr Oncol, 38 (3), 187-91; discussion 192
DOI 10.1002/mpo.1308, PubMed 11836719
Circulating tumor cells in the peripheral blood and bone marrow of patients with ovarian carcinoma do not predict prognosis
Cancer, 94 (3), 707-12
DOI 10.1002/cncr.10250, PubMed 11857303
A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients
Eur J Gynaecol Oncol, 23 (5), 383-9
PubMed 12440808
[Examination, treatment and follow-up of ovarian cancer in Norway]
Tidsskr Nor Laegeforen, 121 (23), 2696-700
PubMed 11699376
Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma
Lancet, 357 (9251), 176-82
DOI 10.1016/S0140-6736(00)03590-X, PubMed 11213094
Long-term results from a phase II study of paclitaxel combined with doxorubicin in recurrent platinum refractory ovarian cancer
Eur J Gynaecol Oncol, 22 (3), 223-7
PubMed 11501778
Tamoxifen in the treatment of recurrent ovarian carcinoma
Eur J Cancer, 36 Suppl 4, S59-61
DOI 10.1016/s0959-8049(00)00228-8, PubMed 11056321
DNA copy number changes in malignant ovarian germ cell tumors
Cancer Res, 60 (11), 3025-30
PubMed 10850452
Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
J Natl Cancer Inst, 92 (9), 699-708
DOI 10.1093/jnci/92.9.699, PubMed 10793106
Effects of paclitaxel on CA-125 serum levels in ovarian cancer patients
Gynecol Oncol, 76 (3), 326-30
DOI 10.1006/gyno.1999.5699, PubMed 10684705
Randomized study on adjuvant chemotherapy in stage I high-risk ovarian cancer with evaluation of DNA-ploidy as prognostic instrument
Ann Oncol, 11 (3), 281-8
DOI 10.1023/a:1008399414923, PubMed 10811493
[DNA ploidy in epithelial ovarian cancer--an independent prognostic factor]
Tidsskr Nor Laegeforen, 120 (1), 43-9
PubMed 10815478
Long-term follow-up of neoadjuvant cisplatin and 5-fluorouracil chemotherapy in bulky squamous cell carcinoma of the cervix
Acta Oncol, 38 (4), 517-20
DOI 10.1080/028418699432077, PubMed 10418721
Long-term results from a phase II study of single agent paclitaxel (Taxol) in previously platinum treated patients with advanced ovarian cancer: the Nordic experience
Ann Oncol, 9 (12), 1301-7
DOI 10.1023/a:1008400324892, PubMed 9932160
Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status
Br J Cancer, 78 (3), 375-81
DOI 10.1038/bjc.1998.502, PubMed 9703286
Carboplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Eur J Gynaecol Oncol, 19 (6), 524-8
PubMed 10215433
Paclitaxel- and docetaxel-dependent activation of CA-125 expression in human ovarian carcinoma cells
Cancer Res, 57 (17), 3818-22
PubMed 9288793
Paclitaxel in untreated FIGO stage III suboptimally resected ovarian cancer
Ann Oncol, 8 (8), 803-6
DOI 10.1023/a:1008230909599, PubMed 9332691
Tamoxifen in the treatment of recurrent ovarian carcinoma
Int. J. Gynecol. Cancer, 7 (4), 256-261
DOI 10.1046/j.1525-1438.1997.00463.x
DNA ploidy and expression of p53 and C-erbB-2 in extramammary Paget's disease of the vulva
Gynecol Oncol, 64 (1), 88-92
DOI 10.1006/gyno.1996.4517, PubMed 8995553
Cisplatin resistance is associated with reduced interferon-gamma-sensitivity and increased HER-2 expression in cultured ovarian carcinoma cells
Br J Cancer, 76 (10), 1328-32
DOI 10.1038/bjc.1997.556, PubMed 9374379
The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma
Gynecol Oncol, 62 (2), 254-9
DOI 10.1006/gyno.1996.0224, PubMed 8751558
Human papilloma virus has no prognostic significance in cervical carcinoma
Eur J Cancer, 32A (8), 1349-53
DOI 10.1016/0959-8049(96)00089-5, PubMed 8869098
Malignant melanoma of the vulva FIGO stage I: Evaluation of prognostic factors in 43 patients with emphasis on DNA ploidy and surgical treatment
Gynecol Oncol, 61 (2), 253-8
DOI 10.1006/gyno.1996.0135, PubMed 8626143
Cisplatin/5-fluorouracil treatment of recurrent cervical carcinoma: a phase II study with long-term follow-up
Gynecol Oncol, 60 (3), 387-92
DOI 10.1006/gyno.1996.0059, PubMed 8774643
Prognosis and management of borderline tumours of the ovary
Curr Opin Obstet Gynecol, 8 (1), 12-6
PubMed 8777251
State of art in endometrial carcinoma
4TH CONGRESS OF THE EUROPEAN SOCIETY FOR GYNAECOLOGICAL ENDOSCOPY: THE UTERUS THROUGHOUT THE WOMAN'S LIFE, 107-115
No prognostic impact of flow-cytometric measured DNA ploidy and S-phase fraction in cancer of the uterine cervix: a prospective study of 465 patients
Gynecol Oncol, 57 (1), 79-85
DOI 10.1006/gyno.1995.1102, PubMed 7705705
Influence of HSP27 and steroid receptor status on provera sensitivity, DNA-ploidy and survival of females with endometrial cancer
Int J Gynecol Cancer, 5 (2), 94-100
DOI 10.1046/j.1525-1438.1995.05020094.x, PubMed 11578461
The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma
Acta Oncol, 34 (6), 797-802
DOI 10.3109/02841869509127189, PubMed 7576748
Flow cytometric DNA ploidy and S-phase heterogeneity in advanced ovarian carcinoma
Cancer, 73 (7), 1870-7
DOI 10.1002/1097-0142(19940401)73:7<1870::aid-cncr2820730716>3.0.co;2-3, PubMed 8137213
Human papillomavirus infection in Norwegian women with cervical cancer
APMIS, 102 (2), 122-8
DOI 10.1111/j.1699-0463.1994.tb04856.x, PubMed 8167008
Evaluation of deoxyribonucleic acid ploidy and S-phase fraction as prognostic parameters in advanced epithelial ovarian carcinoma: a prospective study
Am J Obstet Gynecol, 170 (2), 479-87
DOI 10.1016/s0002-9378(94)70215-2, PubMed 8116701
DNA ploidy; the most important prognostic factor in patients with borderline tumors of the ovary
Int J Gynecol Cancer, 3 (6), 349-358
DOI 10.1046/j.1525-1438.1993.03060349.x, PubMed 11578368
Are borderline tumors of the ovary overtreated both surgically and systemically? A review of four prospective randomized trials including 253 patients with borderline tumors
Gynecol Oncol, 51 (2), 236-43
DOI 10.1006/gyno.1993.1279, PubMed 8276300
Genetic alterations of the TP53 gene, p53 protein expression and HPV infection in primary cervical carcinomas
J Pathol, 171 (2), 105-14
DOI 10.1002/path.1711710207, PubMed 8283348
Evaluation of serum CA 125 level as a tumor marker in borderline tumors of the ovary
Int J Gynecol Cancer, 3 (5), 299-303
DOI 10.1046/j.1525-1438.1993.03050299.x, PubMed 11578361
Analysis of prognostic factors in stage I epithelial ovarian carcinoma: importance of degree of differentiation and deoxyribonucleic acid ploidy in predicting relapse
Am J Obstet Gynecol, 169 (1), 40-52
DOI 10.1016/0002-9378(93)90129-7, PubMed 8333474
A retrospective study of 370 borderline tumors of the ovary treated at the Norwegian Radium Hospital from 1970 to 1982. A review of clinicopathologic features and treatment modalities
Cancer, 71 (5), 1810-20
DOI 10.1002/1097-0142(19930301)71:5<1810::aid-cncr2820710516>3.0.co;2-v, PubMed 8383580
Molecular and biological factors in the pathogenesis of ovarian cancer
Ann Oncol, 4 Suppl 4, 3-16
DOI 10.1093/annonc/4.suppl_4.s3, PubMed 8312207
Bleomycin-ifosfamide-cis-platinum (BIP) in pelvic recurrence of previously irradiated cervical carcinoma: a second look
Gynecol Oncol, 46 (2), 203-7
DOI 10.1016/0090-8258(92)90256-i, PubMed 1379961
Comparison of HPV detection in parallel biopsies and cervical scrapes by PCR
APMIS, 100 (8), 752-6
DOI 10.1111/j.1699-0463.1992.tb03995.x, PubMed 1325806
Flow cytometric DNA measurements in squamous cell carcinoma of the vulva: an important prognostic method
Int J Gynecol Cancer, 2 (4), 169-174
DOI 10.1046/j.1525-1438.1992.02040169.x, PubMed 11576255
Prognostic value of pre- and postoperative serum CA 125 levels in ovarian cancer: new aspects and multivariate analysis
Obstet Gynecol, 79 (6), 1002-10
PubMed 1579296
Cancer of the endometrium: value of MR imaging in determining depth of invasion into the myometrium
AJR Am J Roentgenol, 157 (6), 1221-3
DOI 10.2214/ajr.157.6.1950869, PubMed 1950869
Intraperitoneal antineoplastic agents in the management of ovarian cancer
Eur J Surg Suppl (561), 83-6
PubMed 1720054
[A phase II study of 5-fluorouracil/cisplatin in recurrent cervical cancer]
Tidsskr Nor Laegeforen, 110 (21), 2759-62
PubMed 2219049
Cellular DNA content as a new prognostic tool in patients with borderline tumors of the ovary
Gynecol Oncol, 38 (3), 452-7
DOI 10.1016/0090-8258(90)90090-8, PubMed 2172121
A phase II study of 5-fluorouracil/cisplatinum in recurrent cervical cancer
Acta Oncol, 29 (1), 25-8
DOI 10.3109/02841869009089987, PubMed 2310600
A phase II study of etoposide combined with ifosfamide as second-line therapy in cisplatin-resistant ovarian carcinomas
Cancer Chemother Pharmacol, 26 Suppl, S45-7
DOI 10.1007/BF00685418, PubMed 2347051
Colony-forming ability of human ovarian carcinomas in the Courtenay soft agar assay
Anticancer Res, 9 (6), 1577-82
PubMed 2483300
Primary adenocarcinoma localized to the fallopian tubes: report on 33 cases
Gynecol Oncol, 30 (2), 183-6
DOI 10.1016/0090-8258(88)90022-4, PubMed 3371742
Intrauterine growth in twin pregnancies: prediction of fetal growth retardation
Obstet Gynecol, 66 (1), 63-8
PubMed 3892389
A study of the incidence of neonatal conjunctivitis and of its bacterial causes including Chlamydia trachomatis. Clinical examination, culture and cytology of tear fluid
Acta Ophthalmol (Copenh), 62 (3), 461-71
DOI 10.1111/j.1755-3768.1984.tb08426.x, PubMed 6380204
A study of inclusion conjunctivitis in newborn and young adults. Clinical picture, culture, conjunctival scrapings and cytology of the tear fluid in 12 cases
Acta Ophthalmol (Copenh), 61 (6), 969-84
DOI 10.1111/j.1755-3768.1983.tb01484.x, PubMed 6362323
Review articles
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
PubMed 19899396
Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature
J Clin Oncol, 25 (20), 2909-20
DOI 10.1200/JCO.2007.11.1013, PubMed 17617522
[Borderline tumors of the ovary]
Tidsskr Nor Laegeforen, 120 (23), 2764-70
PubMed 11107921
Management of borderline tumors of the ovary: state of the art
Semin Oncol, 25 (3), 372-80
PubMed 9633850
DNA flow cytometry as a new prognostic factor in ovarian malignancies. A review
Acta Obstet Gynecol Scand Suppl, 155, 95-7
DOI 10.1111/j.1600-0412.1992.tb00013.x, PubMed 1502897
[DNA examinations in gynecological cancer and breast cancer]
Tidsskr Nor Laegeforen, 111 (13), 1638-42
PubMed 2063365
Usefulness of flow cytometric DNA measurements in genital and breast cancers
Eur J Gynaecol Oncol, 10 (3), 191-5
PubMed 2659366
Other articles
Human germ cell tumours: expression of gamma-glutamyl transpeptidase and sensitivity to cisplatin
Br J Cancer, 81 (1), 75-9
DOI 10.1038/sj.bjc.6690653, PubMed 10487615
DNA ploidy in epithelial ovarian cancer: a new independent prognostic factor?
Gynecol Oncol, 53 (1), 1-4
DOI 10.1006/gyno.1994.1077, PubMed 8175006
Papillomaviruses, p53, and cervical cancer
Lancet, 339 (8805), 1350-1
PubMed 1350005
HLA antigens and cervical carcinoma
Nature, 356 (6364), 23
DOI 10.1038/356023a0, PubMed 1538776
Comparison between flow cytometry and image cytometry in ploidy distribution assessments in gynecologic cancer
Cytometry, 13 (3), 314-21
DOI 10.1002/cyto.990130314, PubMed 1576895
The close follow-up of immunosuppressed renal recipient women through colposcopy, cervical biopsy and FCM DNA content analysis
Eur J Cancer, 27 (3), 302
DOI 10.1016/0277-5379(91)90531-h, PubMed 1827319